Table 4.
Adjusted ORs for TMAO related to DR in T2DM patients across subgroups
| Subgroups | OR (95% CI) a | P | P-interaction |
|---|---|---|---|
| Age, year | 0.098 | ||
| ≤ 60 | 2.76 (1.28–5.97) | 0.010 | |
| > 60 | 2.65 (1.07–6.57) | 0.035 | |
| Gender | 0.006 | ||
| Male | 4.17 (1.73–10.04) | 0.001 | |
| Female | 2.13 (0.97–4.65) | 0.059 | |
| BMI, kg/m2 | 0.108 | ||
| ≤ 24 | 3.35 (1.42–7.91) | 0.006 | |
| > 24 | 2.31 (1.04–5.09) | 0.039 | |
| Diabetes duration, year | 0.159 | ||
| ≤ 11 | 3.57 (1.55–8.23) | 0.003 | |
| > 11 | 2.11 (0.96–4.61) | 0.063 | |
| Hypertension | 0.101 | ||
| No | 3.53 (1.32–9.43) | 0.012 | |
| Yes | 2.25 (1.09–4.65) | 0.029 |
TMAO, trimethylamine-N-oxide; T2DM, type 2 diabetes mellitus; DR, diabetic retinopathy; BMI, body mass index; OR, odds ratio; CI, confidence interval; SD, standard deviation; ln, logarithmic
aORs and their corresponding 95% CI per SD increment in the ln-transformed TMAO were obtained by binary logistic regression adjusted for age, gender, BMI, diabetes duration and hypertension